AGIOS PHARM
NASDAQ: AGIO (Agios Pharmaceuticals, Inc.)
Kemas kini terakhir: 13 minit lalu34.90
3.58 (11.43%)
| Penutupan Terdahulu | 31.32 |
| Buka | 31.61 |
| Jumlah Dagangan | 1,787,876 |
| Purata Dagangan (3B) | 1,106,617 |
| Modal Pasaran | 2,083,595,648 |
| Harga / Jualan (P/S) | 20.41 |
| Harga / Buku (P/B) | 1.99 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2026 |
| Margin Keuntungan | 1,798.26% |
| Margin Operasi (TTM) | -1,221.97% |
| EPS Cair (TTM) | 11.54 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.61% |
| Nisbah Semasa (MRQ) | 18.50 |
| Aliran Tunai Operasi (OCF TTM) | -401.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -237.66 M |
| Pulangan Atas Aset (ROA TTM) | -22.88% |
| Pulangan Atas Ekuiti (ROE TTM) | 60.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Agios Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 5.0 |
| AI Insight | NA |
| Purata | 0.29 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.65% |
| % Dimiliki oleh Institusi | 101.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Lynx1 Capital Management Lp | 30 Jun 2026 | 3,408,937 |
| Erste Asset Management Gmbh | 30 Jun 2026 | 2,154,900 |
| Nomura Investment Management Business Trust | 30 Jun 2026 | 2,110,809 |
| Assenagon Asset Management S.A. | 30 Sep 2026 | 1,886,412 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |